EDEN PRAIRIE, Minn.–(BUSINESS WIRE)–Surmodics, Inc. (NASDAQ: SRDX), the global leader in medical device coating technologies, announced the commercial launch of its most advanced hydrophilic medical device coating technology, Preside™ hydrophilic coatings.
Preside hydrophilic coatings complement Surmodics’ existing Serene hydrophilic coatings by providing customers with a unique low-friction and low-particulate generation coating to further enhance distal access for neurovascular applications, as well as improve crossing for challenging coronary lesions or chronic total occlusions.
Preside hydrophilic coatings are specifically formulated to meet the challenge of achieving the right balance of enhanced lubricity (reduction in friction) and excellent coating durability (resulting in low particulates) for the next-generation of Neurovascular, Coronary and Peripheral vascular devices. Surmodics’ Preside hydrophilic coatings allow customers to leverage their existing coating processes resulting in easy implementation in a manufacturing environment.
“Hydrophilic coatings are an essential feature to help medical devices access and navigate tortuous vascular pathways, allowing physicians to reach distal treatment sites for improved therapeutic outcomes,” said Charlie Olson, Senior Vice President, and President of Surmodics’ Medical Device Coatings business. “We are pleased to secure the first 510(k) device clearance that leverages this new technology. Our Preside hydrophilic coatings strengthen our existing portfolio and sets a new performance standard for the industry, and the medical device manufacturers we serve.”
About Preside™ Hydrophilic Coatings
Surmodics’ Preside™ hydrophilic coatings combine a unique industry-leading lubricity and durability, including dramatically improved particulate reduction to address today’s increasing regulatory requirements.
Preside hydrophilic coatings successfully bond to a wide variety of substrates present on today’s market-leading neurovascular, coronary and peripheral catheters. Preside hydrophilic coatings are applied using Surmodics’ patented Photolink™ UV curing process, which covalently bonds surface treatments to substrates at ambient temperature. This flexible technology can easily be incorporated into existing manufacturing processes and can markedly reduce production time and reagent costs compared to both thermal-curing and alternative UV-based chemistries and processes.
Surmodics’ chemistries have a proven regulatory record with leading coronary, peripheral, neurovascular and structural heart device applications. Surmodics collaborates with licensed customers to satisfy coating product performance specifications, while navigating through regulatory requirements to accelerate our customer’s speed to market.
About Surmodics, Inc.
Surmodics is a leading provider of performance coating technologies for intravascular medical devices and chemical and biological components for in vitro diagnostic immunoassay tests and microarrays. Surmodics also develops and commercializes highly differentiated vascular intervention medical devices that are designed to address unmet clinical needs and engineered to the most demanding requirements. This key growth strategy leverages the combination of the company’s expertise in proprietary surface modification and drug-delivery coating technologies, along with its device design, development, and manufacturing capabilities. The company’s mission is to improve the detection and treatment of disease. Surmodics is headquartered in Eden Prairie, Minnesota. For more information, visit www.surmodics.com. The content of Surmodics’ website is not part of this press release or part of any filings that the company makes with the Securities and Exchange Commission.
Surmodics Investor Inquiries:
Jack Powell, Investor Relations